Realm Therapeutics Announces Results of 2018 Annual General Meeting

Thursday, June 14, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

MALVERN, Pa., June 14, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM) a clinical stage biopharmaceutical company

focused on developing novel therapeutics in immune-mediated diseases, today announces that all Resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today.  Proxy figures will be displayed shortly on the Company's
website at www.realmtx.com. 

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics that target the interplay between innate and adaptive immunity. The Company's programs seek to influence immune signaling and change the course of immune-mediated diseases in adults and children. Realm's lead drug development program utilizes the Company's proprietary immunomodulatory technology for the treatment of Atopic Dermatitis, and the Company is exploring its efficacy in other dermatology indications which include Acne Vulgaris, and Psoriasis, as well as other therapeutic areas. For more information on Realm Therapeutics please visit www.realmtx.com.

G-RLM

 

 

Cision View original content:http://www.prnewswire.com/news-releases/realm-therapeutics-announces-results-of-2018-annual-general-meeting-300666342.html

SOURCE Realm Therapeutics



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store